[USING INTERFERON INDUCTORS IN THERAPY OF PRE-SCHOOL-AGE PATIENTS WITH REACTIVATED EPSTEIN - BARR VIRUS INFECTION.]

Area of Science:

• Pediatrics
• Virology
• Immunology

Background:

• Reactivated Epstein-Barr virus infection in pre-school children often presents as mononucleosis.
• Complex therapy is standard for managing Epstein-Barr virus (EBV) infections.

Purpose of the Study:

• To assess the efficacy of meglumine acridone acetate (cycloferon) as part of complex therapy for EBV mononucleosis in pre-school patients.
• To evaluate the impact of different cycloferon treatment durations on clinical outcomes.

Main Methods:

• The study involved pre-school-age patients diagnosed with reactivated Epstein-Barr virus infection.
• Patients received complex therapy including cycloferon, with varying treatment schedules (short-term vs. prolonged).
• Clinical and hematological symptoms, treatment duration, and recurrence rates were monitored.

Main Results:

• Cycloferon inclusion in complex therapy led to regression of key clinical-hematological symptoms during the progression period.
• Average clinical treatment duration decreased by 4.39 bed days.
• Prolonged cycloferon treatment showed maximum efficacy, improving residual phenomena, reducing recurrence, and lowering acute respiratory complications compared to short-term treatment and controls.

Conclusions:

• Meglumine acridone acetate (cycloferon) is an effective interferon inductor for managing EBV mononucleosis in children.
• Prolonged cycloferon therapy offers superior benefits, including reduced complications and recurrences.
• Cycloferon contributes to a smoother recovery and fewer residual symptoms in pediatric EBV infections.